Business Areas
1. Pharmaceuticals
LG Life Sciences(LGLS) has an extensive sales and marketing network spanning over 75 countries with LGLS technology based products. Among these products, Factive is a representative Korean drug which is yet only FDA approved novel drug in Korea. Factive is a dual targeting fluroquinolone antibiotic selling over 15 countries worldwide. Also, LGLS is a major hepatitis B vaccine supplier of UN agencies and has exported to more than 75 countries in the world. LGLS hepatitis B vaccine, Euvax B takes up over 50% of UNICEF supply. In 2007, an additional success to domestic marketing, Hyruan Plus, an osteoarthritis treatment has achieved CE marking and now is marketed over 20 countries including Europe. Hyruan Plus is highly purified hyaluronic acid, processed by microbial fermentation which ensures to be BSE-free. Showing LGLS’ advanced bioengineering technology, LGLS developed one of very few biosimilar recombinant human erythropoietin and follitropin that are registered and marketed over 15 countries. In addition to Euvax B, and Factive, LGLS has many infertility treatments, ophthalmic surgical interventions, diagnostics drugs, animal drug, and pharmaceutical drug intermediates that are exported all over the world.
2. Specialty Chemicals
For nearly 20 years, LG Life Sciences has been developing and marketing new generation agrochemicals. The company’s earlier product line consisted of pyrethroid insecticides, including Cypermethrin, Deltamethrin, and Lambdacyhalothrin. LGLS produced these insecticides because manufacturing such products was a technical challenge in the early to mid-1980s. As soon as pyrethroid chemistry ceased to be a challenge, the company moved on to a new technical challenge. LGLS now has three new molecules(Pyanchor, Guardian, Fluxo) being developed globally. In the past two years, the structure of LGLS’s crop protection business has changed significantly, from technology to business integration, to achieve sustainable and healthy growth. The company emphasizes strong global partnerships with multinationals regarding its proprietary molecules, while strengthening its domestic operations through strategic ties with local and independent sales networks. Since 2000, LGLS has been expanding into the generic product sector in the U.S., the world’s largest agrochemical market. In addition to Permethrin, LGLS registered three of its generic products with the EPA in 2006, Metalaxyl, Lambda-Cyhalothrin, and Esfenvalerate. LGLS plans to continue expanding its U.S. business by introducing additional products.
3. Diagnostics
LG Life Sciences has invested and researched constantly over the past two decades in diagnostics areas and has developed in-vitro diagnostics for Hepatitis C(first in Korea), Malaria antibodies(first in the world), HIV antigens and antibodies, Syphillis and Hepatitis B virus. LGLS’s goal in diagnostics R&D is to raise the competitiveness of current products and to cultivate a steady stream of strategic products for the future. To this end, core competencies are being strengthened and its efforts focus on new product development. The trend in diagnostic medicine technology today is to generate value by incorporating information, nanotechnologies and biotechnologies. LGLS is building upon its world-class technology in infections diseases and accelerating R&D research to secure a technological edge in ELISA, real-time PCR and several types of biochips.
Read more about this topic: LG Life Sciences
Famous quotes containing the words business and/or areas:
“Young men of the fairest promise, who begin life upon our shores, inflated by the mountain winds, shined upon by all the stars of God, find the earth below not in unison with these,—but are hindered from action by the disgust which the principles on which business is managed inspire, and turn drudges, or die of disgust,—some of them suicides.”
—Ralph Waldo Emerson (1803–1882)
“The point is, that the function of the novel seems to be changing; it has become an outpost of journalism; we read novels for information about areas of life we don’t know—Nigeria, South Africa, the American army, a coal-mining village, coteries in Chelsea, etc. We read to find out what is going on. One novel in five hundred or a thousand has the quality a novel should have to make it a novel—the quality of philosophy.”
—Doris Lessing (b. 1919)